Large for 136 per 1,000 RR 1.66 8,186 (1.11 to 2.48) (1 observational study) gestational age 82 per 1,000 (91 to 203) LOW 1 (>90th percentile) Macrosomia 174 per 1,000 RR 1.12 8,186 155 per 1,000 (121 to 250) (>4,000g) (0.78 to 1.61) (1 observational study) LOW 1 *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio Working Group grades of evidence High quality: We are very confident that the true effect lies close to that of the estimate of the effect Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect Source: Hughes et al 2014. Note that this was included in MoH NZ 2014 but is presented spearatley here to inform the analysis. Data from a single observational study with low rates of participation in reference testing Pregnancy outcomes associated with early treatment compared to later treatment for women with HbA1c 41–49 mmol/mol Pregnant women Patient or population: New Zealand Setting: Intervention: treatment (<24 weeks) Comparison: Later treatment (24 weeks) Outcomes Anticipated absolute effects* (95% CI) Relative effect of participants Quality of the Comments № (95% CI) (studies) evidence (GRADE) Risk with later Risk with early treatment treatment (24 wk) (<24 wk) Perinatal death 0 per 1,000 not estimable 285 0 per 1,000 (1 observational study) (0 to 0) LOW 1
Large for gestational age (>90th percentile) 82 per 1,000 136 per 1,000 (91 to 203) RR 1.66 (1.11 to 2.48) 8,186 (1 observational study) LOW 1 Macrosomia (>4,000g) 155 per 1,000 174 per 1,000 (121 to 250) RR 1.12 (0.78 to 1.61) 8,186 (1 observational study) LOW 1 *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio Working Group grades of evidence High quality: We are very confident that the true effect lies close to that of the estimate of the effect Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect Source: Hughes et al 2014. Note that this was included in MoH NZ 2014 but is presented spearatley here to inform the analysis. Data from a single observational study with low rates of participation in reference testing Pregnancy outcomes associated with early treatment compared to later treatment for women with HbA1c 41–49 mmol/mol Patient or population: Pregnant women Setting: New Zealand Intervention: treatment (<24 weeks) Comparison: Later treatment (24 weeks) Outcomes Anticipated absolute effects* (95% CI) Relative effect (95% CI) № of participants (studies) Quality of the evidence (GRADE) Comments Risk with later treatment (24 wk) Risk with early treatment (<24 wk) Perinatal death 0 per 1,000 0 per 1,000 (0 to 0) not estimable 285 (1 observational study) LOW 1
Detecting%20undiagnosed%20diabetes%20evidence%20evaluation%2016May17.docx